NCT04672707已完成1 期
Study on the Pharmacokinetics of Bromine Hexane Hydrochloride Tablets in Healthy Adults
Second Affiliated Hospital of Wenzhou Medical University1 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2020年12月28日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- Cmax
研究概览
简要总结
This clinical study is about increasing the dosage of bromine hexane hydrochloride to safety volume and continue to give it frequently in the new crown virus treatment could improve the efficacy.
详细描述
The purpose is to study the pharmacokinetic characteristics and safety of bromine hexane hydrochloride in healthy adults after oral administration of bromine hexane hydrochloride tablets. Then to explore the mechanism related to the role of transmembrane serine proteases (TMPRSSs) through the study, and to provide the basis for the clinical rational administration of bromine hexane hydrochloride tablets.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult males and non-pregnant non-lactating females aged 18-55 years, including boundary values, trial period Over 55 years of age);
- •Male body weight ≥50 kg, female body weight ≥45 kg, body mass index (BMI )19,282 Between, including boundary values;
- •Health, no heart, liver, kidney, digestive tract, nervous system, mental disorders and metabolic disease history;
- •Sign informed consent before the trial, fully understand the content, process and possible adverse reactions, and communicate well with the researchers.
排除标准
- •Have participated in any clinical trial within 90 days before the trial or plan to participate in other clinical trials during the trial;
- •Have undergone major surgery within 90 days before the trial or plan to undergo surgery within 3 months after the trial;
- •Blood loss or donation of more than 300 blood mL (excluding female physiological blood loss) within 90 days prior to the trial, or blood transfusion;
- •Suffering from esophageal reflux, gastric bleeding or peptic ulcer disease within 180 days prior to the trial, more than once a week with heartburn, or any surgical procedure that may affect drug absorption (e.g. cholecystectomy);
- •a person with a specific history of allergies (asthma, urticaria, eczema, etc.), or an allergic constitution (e.g. allergic to two or more drugs, food or pollen), or a known component of the drug*or analogues/lactose allergy/intolerance;
- •*The main components of the test drug: bromine hexane hydrochloride, excipients: starch, lactose, magnesium stearate.
- •Use of any medication within 28 days prior to the trial, including the use of prescription, over-the-counter and/or alternative medicines (e.g., medicinal meals, herbal medicines, hemostatic or health products) and the use of hormonal contraception or vaccines;
- •History of substance abuse;
- •Urine screening for substance abuse (tetrahydrocannabinol, benzodiazepine, barbiturates, morphine, cocaine, methamphetamine) was positive;
- •More than 3 cigarettes per day during the 90 days before the test; Alcoholism, Over 7 drinks per week for women and over 14 drinks per week for men (1=150 mL wine =360 mL beer and 45 spirits);
- •Positive breath test;
- •The body temperature (ear temperature)≥37.5℃, the respiration was obviously abnormal, and the researchers thought it was not suitable to take part in the experiment. The systolic blood pressure >140 mmHg or <90 mmHg, diastolic blood pressure (diastolic blood pressure) was 90 mmHg or 60 times 100/min or >;
- •Positive human immunodeficiency virus antibody (HIV-Ab), hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab) or Treponema pallidum specific antibody (TPHA);
- •There are special requirements for diet, during the test can not comply with a unified diet;
- •Subjects refused to comply with the 48-hour ban on caffeine, alcohol, grapefruit and food (including tea, chocolate, coffee, cola, etc.);
- •Participants with partners refused to use effective contraception within 180 days from screening to completion of the trial；
- •Female subjects were positive for blood/urine pregnancy;
- •(c) Persons with renal insufficiency, impairment or previous urinary system disease;
- •hereditary galactose intolerance, lactase deficiency, or glucose-galactose malabsorption;
- •Halo acupuncture, halo blood and venous blood collection difficulties;
- •The physical examination has an obvious abnormality, and the researcher thinks it is not suitable to participate in the experiment;
- •Electrocardiogram examination has an obvious abnormality, and the researcher thinks it is not suitable to participate in the experiment;
- •Blood biochemistry, blood routine, urine routine examination have obvious abnormal, and the researchers think it is not suitable to participate in the test;
- •The subjects may not be able to complete the study for other reasons or may not be suitable for participation in the study.
研究组 & 干预措施
Group A
Experimental
Bromhexine Hydrochloride Tablet, 32 mg, 8 mg 4 tablets, three times a day, for 2 days
干预措施: Bromhexine Hydrochloride Tablet (Drug)
Group B
Experimental
Bromhexine Hydrochloride Tablet, 48 mg, 8 mg 6 tablets, three times a day, continuous service within 2 days
干预措施: Bromhexine Hydrochloride Tablet (Drug)
Group C
Experimental
Bromhexine Hydrochloride Tablet, 64 mg ,8 mg spec 8 tablets ,3 times daily ,2 days in succession)
干预措施: Bromhexine Hydrochloride Tablet (Drug)
Group D
Experimental
Bromhexine Hydrochloride Tablets, 80 mg ,8 mg Standard preparation 10 tablets ,3 times a day ,2 day
干预措施: Bromhexine Hydrochloride Tablet (Drug)
结局指标
主要结局
Cmax
时间窗: up to 48 hours
Maximum observed concentration
次要结局
- Clearance rate（CL）(up to 48 hours)
- Area under curve (AUC 0-16h)(up to 48 hours)
- AUC(AUC to infinity)(up to 48 hours)
- Vd(up to 48 hours)
- t1/2(5 hour)
- λz(up to 48 hours)
- AUC_%Extrap(up to 48 hours)
- Time of maximum concentration (Tmax)(2 to 2.5 hours)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)Novel Coronavirus Pneumonia2019-nCoVNCT04273763Second Affiliated Hospital of Wenzhou Medical University18
招募中
3 期
Effect of Bromhexine Hydrochloride on patients with COVID-19IRCT20200317046797N4Tabriz University of Medical Sciences60
已完成
2 期
The efficacy of bromhexine hydrochloride in the prevention of COVID-19 diseaseIRCT20200317046797N7Tabriz University of Medical Sciences3,500
已完成
2 期
Evaluation of the efficacy and safety of bromhexine administration in COVID-19COVID-19 pneumonia.COVID-19, virus identifiedU07.1IRCT20151227025726N24Shahid Beheshti University of Medical Sciences100
已完成
3 期
Verification of the efficacy of Bromhexine-hydrochloride in treatment of patients with COVID19 diseaseIRCT20200818048444N1Tabriz University of Medical Sciences1,300